Elutia Appoints Ryan Marques, Ph.D., MBA as Vice President of Operations
Elutia Inc. (Nasdaq: ELUT) has appointed Ryan Marques, Ph.D., MBA as Vice President of Operations. Dr. Marques brings over 20 years of experience in leading operations teams across manufacturing, quality assurance, supply chain, and technical services in the device and pharmaceutical industries. This appointment comes as Elutia prepares to launch EluPro®, the world's first FDA-cleared antibiotic-eluting BioEnvelope, in the second half of 2024.
Dr. Marques previously served as Head of U.S. Operations at Nobelpharma America and has held leadership positions at Next Breath Inc./Aptar Pharma and Canon BioMedical. He holds a Ph.D. in Molecular Microbiology and Immunology and an MBA from the University of Maryland. His expertise is expected to be instrumental in Elutia's growth and product expansion.
Elutia Inc. (Nasdaq: ELUT) ha nominato Ryan Marques, Ph.D., MBA come Vicepresidente delle Operazioni. Il Dr. Marques porta con sé oltre 20 anni di esperienza nella guida di team operativi nei settori della produzione, assicurazione qualità, supply chain e servizi tecnici nelle industrie dei dispositivi e farmaceutica. Questa nomina arriva mentre Elutia si prepara a lanciare EluPro®, il primo BioEnvelope a rilascio di antibiotici approvato dalla FDA al mondo, nella seconda metà del 2024.
Il Dr. Marques in precedenza ha ricoperto il ruolo di Responsabile delle Operazioni negli Stati Uniti presso Nobelpharma America e ha occupato posizioni di leadership presso Next Breath Inc./Aptar Pharma e Canon BioMedical. Ha conseguito un dottorato in Microbiologia Molecolare e Immunologia e un MBA presso l'Università del Maryland. Si prevede che la sua esperienza sarà fondamentale per la crescita e l'espansione dei prodotti di Elutia.
Elutia Inc. (Nasdaq: ELUT) ha nombrado a Ryan Marques, Ph.D., MBA como Vicepresidente de Operaciones. El Dr. Marques aporta más de 20 años de experiencia liderando equipos de operaciones en manufactura, aseguramiento de la calidad, cadena de suministro y servicios técnicos en las industrias de dispositivos y farmacéutica. Este nombramiento se produce mientras Elutia se prepara para lanzar EluPro®, el primer BioEnvelope con liberación de antibióticos aprobado por la FDA en el mundo, en la segunda mitad de 2024.
El Dr. Marques anteriormente se desempeñó como Jefe de Operaciones en EE. UU. en Nobelpharma America y ha ocupado puestos de liderazgo en Next Breath Inc./Aptar Pharma y Canon BioMedical. Tiene un doctorado en Microbiología Molecular e Inmunología y un MBA de la Universidad de Maryland. Se espera que su experiencia sea fundamental para el crecimiento y la expansión de productos de Elutia.
Elutia Inc. (Nasdaq: ELUT)는 Ryan Marques, Ph.D., MBA를 운영 부사장으로 임명했습니다. Marques 박사는 기기 및 제약 산업에서 제조, 품질 보증, 공급망 및 기술 서비스 분야의 운영 팀을 이끄는 데 20년 이상의 경험을 가지고 있습니다. 이 임명은 Elutia가 세계 최초의 FDA 승인 항생제 방출 BioEnvelope인 EluPro®를 2024년 하반기에 출시할 준비를 하고 있는 가운데 이루어졌습니다.
Marques 박사는 이전에 Nobelpharma America의 미국 운영 책임자를 역임했으며, Next Breath Inc./Aptar Pharma 및 Canon BioMedical에서 리더십 직책을 맡았습니다. 그는 메릴랜드 대학교에서 분자 미생물학 및 면역학 박사와 MBA를 취득했습니다. 그의 전문성이 Elutia의 성장과 제품 확장에 중요한 역할을 할 것으로 예상됩니다.
Elutia Inc. (Nasdaq: ELUT) a nommé Ryan Marques, Ph.D., MBA au poste de Vice-Président des Opérations. Le Dr Marques apporte plus de 20 ans d'expérience dans la direction d'équipes opérationnelles dans les domaines de la fabrication, de l'assurance qualité, de la chaîne d'approvisionnement et des services techniques dans les secteurs des dispositifs médicaux et pharmaceutiques. Cette nomination intervient alors qu'Elutia se prépare à lancer EluPro®, le premier BioEnvelope à libération d'antibiotiques approuvé par la FDA au monde, dans la seconde moitié de 2024.
Le Dr Marques a précédemment occupé le poste de Responsable des Opérations aux États-Unis chez Nobelpharma America et a occupé des postes de leadership chez Next Breath Inc./Aptar Pharma et Canon BioMedical. Il est titulaire d'un doctorat en Microbiologie Moléculaire et Immunologie ainsi que d'un MBA de l'Université du Maryland. Son expertise devrait être déterminante pour la croissance et l'expansion des produits d'Elutia.
Elutia Inc. (Nasdaq: ELUT) hat Ryan Marques, Ph.D., MBA zum Vizepräsidenten der Operationen ernannt. Dr. Marques bringt über 20 Jahre Erfahrung in der Leitung von operativen Teams in den Bereichen Fertigung, Qualitätssicherung, Lieferkette und technische Dienstleistungen in den Bereichen Geräte und Pharmazie mit. Diese Ernennung erfolgt, während Elutia sich darauf vorbereitet, EluPro®, die weltweit erste von der FDA zugelassene Antibiotika-freisetzende BioEnvelope, im zweiten Halbjahr 2024 auf den Markt zu bringen.
Dr. Marques war zuvor Leiter der US-Operationen bei Nobelpharma America und hatte Führungspositionen bei Next Breath Inc./Aptar Pharma und Canon BioMedical inne. Er hat einen Doktortitel in Molekularer Mikrobiologie und Immunologie sowie einen MBA von der University of Maryland. Seine Expertise wird voraussichtlich entscheidend für das Wachstum und die Produktentwicklung von Elutia sein.
- Appointment of experienced VP of Operations with 20+ years in pharma and device industries
- Preparation for launch of EluPro®, the first FDA-cleared antibiotic-eluting BioEnvelope in H2 2024
- Potential for expanded production capacity and new drug-eluting biomatrix products
- None.
SILVER SPRING, Md., July 31, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, today announced the appointment of Ryan Marques, Ph.D, MBA as Vice President of Operations. Dr. Marques brings more than 20 years of experience leading operations teams across manufacturing, quality assurance, supply chain and technical services in the device and pharmaceutical industries.
“We are pleased to welcome Ryan to the Elutia CRU as our new Vice President of Operations,” said Dr. Randy Mills, Elutia’s Chief Executive Officer. “At Elutia, culture matters, and Ryan has both the experience and character to make him an excellent fit and an effective leader within our growing organization. His extensive operational and manufacturing expertise across both pharma and devices will be instrumental as we launch EluPro®, the world’s first FDA-cleared antibiotic-eluting BioEnvelope, in the second half of 2024.”
Prior to joining Elutia, Dr. Marques served as the Head of U.S. Operations at Nobelpharma America, a pharmaceutical and medical device company dedicated to treating rare and neglected diseases. Before that, he led operations at Next Breath Inc./Aptar Pharma, a contract services provider for pharmaceutical, biotech, and medical device companies, as well as at Canon BioMedical, a medical diagnostics company. Dr. Marques began his industry career by managing manufacturing and technical operations at QIAGEN. Dr. Marques completed his post-doctoral training at the University of Maryland (Center for Vaccine Development) and holds a Ph.D. in Molecular Microbiology and Immunology and an MBA from the Robert H. Smith School of Business, University of Maryland.
“I am honored to join Elutia at such an important time for the Company,” said Dr. Marques. “I am excited to be working as part of the talented Elutia team as we launch EluPro and expand our production capacity for the current product offerings as well as new drug-eluting biomatrix products in development.”
About Elutia
Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.
Forward-Looking Statements
This press release includes certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the launch of EluPro, expansion of production capacity and new product development. These statements are based on the Company’s current expectations or beliefs and are subject to uncertainty and changes in circumstances. Actual results may vary materially from those expressed or implied by the statements here due to changes in economic, business, competitive or regulatory factors, and other risks and uncertainties, including those set forth in the Company’s filings with the SEC under the heading “Risk Factors”. The forward-looking statements in this press release speak only as of the date of this press release. The Company does not undertake any obligation to update or revise these forward-looking statements for any reason, except as required by law.
Investors:
Matt Steinberg
FINN Partners
matt.steinberg@finnpartners.com
FAQ
Who is the new Vice President of Operations at Elutia (ELUT)?
When is Elutia (ELUT) planning to launch EluPro®?
What is Dr. Ryan Marques' background before joining Elutia (ELUT)?
What is EluPro® by Elutia (ELUT)?
